KEYNOTE-A18 : A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

ThreePhase Three

18+Age Over 18

Female Reproductive<br/>System CancersCancer LocationFemale Reproductive
System Cancers

Multiple treatment types,Radiotherapy,Systemic therapy | Female reproductive organsCervix

Trial Overview Read MoreRead more

This phase III trial is evaluating the safety and effectiveness of using chemo-radiotherapy with or without immunotherapy for the treatment of patients with locally advanced cervical cancer .
 

This trial is treating patients with cervical cancer.

This is a systemic therapy and radiotherapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

Cooperative Group

European Network for Gynaecological Oncological Trial Groups & the Gynecologic Oncology Group

Commercial Sponsor

Merck

Summary

Eligible patients will be randomised to receive standard of care chemo-radiotherapy with cisplatin and external beam radiotherapy and brachytherapy, in addition to pembrolizumab or a pembrolizumab-placebo, to understand the impact on progression-free survival and overall survival.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Breast and Gynaecology Research Study Coordinator
breastgynae.oncresearch@monashhealth.org
0491299561

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next